Dr. Michael K. Lim

Hospital Medicine
325 Distel Cir, 
Los Altos, CA 
325 Distel Cir, 
Los Altos, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Lim is a Hospital Medicine provider in Los Altos, California. Dr. Lim is rated as an Experienced provider by MediFind in Thrombectomy. His top areas of expertise are Tarlov Cysts, Arteriovenous Malformation, Gallbladder Disease, Rhizotomy, and Microvascular Decompression.

His clinical research consists of co-authoring 382 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hospital Medicine
Licenses
Hospitalist in CA
Hospital Affiliations
El Camino Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

325 Distel Cir, Los Altos, CA 94022

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase IIa Study Assessing QBS72S For Treating Brain Metastases
Phase IIa Study Assessing QBS72S For Treating Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
A Phase I Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drug: MBG453
Study Phase: Phase 1
Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Biological, Other, Radiation
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
Randomized, Two-arm, Multicenter Study to Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery
Randomized, Two-arm, Multicenter Study to Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery
Enrollment Status: Completed
Publish Date: June 26, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Anti-CD137
Study Phase: Phase 1
A Pilot Study of Stereotactic Radiosurgery Combined With Nivolumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine
A Pilot Study of Stereotactic Radiosurgery Combined With Nivolumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine
Enrollment Status: Completed
Publish Date: November 30, 2021
Intervention Type: Radiation, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 1
A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme
A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination With Anti-PD-1 (Nivolumab) in Patients With First Recurrence of Glioblastoma
Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination With Anti-PD-1 (Nivolumab) in Patients With First Recurrence of Glioblastoma
Enrollment Status: Terminated
Publish Date: July 02, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases
Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases
Enrollment Status: Completed
Publish Date: June 25, 2020
Intervention Type: Radiation
Study Phase: Phase 2
View 10 Less Clinical Trials

382 Total Publications

Colorectal cancer relies on an immunosuppressive cellular topography and genomic adaptations for establishing brain metastases.
Colorectal cancer relies on an immunosuppressive cellular topography and genomic adaptations for establishing brain metastases.
Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025
Similar Doctors
Experienced in Thrombectomy
Dr. Mai T. Le
Hospital Medicine
Experienced in Thrombectomy
Dr. Mai T. Le
Hospital Medicine
3132 W March Ln Ste 5, 
Stockton, CA 
 (56.6 miles away)
209-475-5500
Languages Spoken:
English
See accepted insurances

Mai Le is a Hospital Medicine provider in Stockton, California. Dr. Le is rated as an Experienced provider by MediFind in Thrombectomy. Her top areas of expertise are Protein Deficiency, Vitamin D Deficiency, and Thrombectomy.

Experienced in Thrombectomy
Dr. Bhaskara V. Garimella
Pulmonary Medicine | Hospital Medicine
Experienced in Thrombectomy
Dr. Bhaskara V. Garimella
Pulmonary Medicine | Hospital Medicine

Permanente Medical Group Inc

270 International Cir, 
San Jose, CA 
 (19.9 miles away)
408-972-3000
Languages Spoken:
English
See accepted insurances

Bhaskara Garimella is a Pulmonary Medicine specialist and a Hospital Medicine provider in San Jose, California. Dr. Garimella is rated as an Experienced provider by MediFind in Thrombectomy. His top areas of expertise are COVID-19 and Thrombectomy.

Experienced in Thrombectomy
Dr. Serena B. Del Mundo
Internal Medicine | Hospital Medicine
Experienced in Thrombectomy
Dr. Serena B. Del Mundo
Internal Medicine | Hospital Medicine

Geniemd Medical Group Mo PC

6612 Owens Dr, 
Pleasanton, CA 
 (30.5 miles away)
928-460-9191
Languages Spoken:
English
See accepted insurances

Serena Del Mundo is a Hospital Medicine provider in Pleasanton, California. Dr. Del Mundo is rated as an Experienced provider by MediFind in Thrombectomy. Her top areas of expertise are Thrombectomy and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lim's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile